You are currently viewing a new version of our website. To view the old version click .
Medical Sciences Forum
  • Abstract
  • Open Access

1 November 2022

Synthesis of Novel 2-Phenylindole Analogues as Antifungal and Antibacterial Agents †

and
Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmaceutical Sciences, Shihezi University, Shihezi 832002, China
*
Author to whom correspondence should be addressed.
Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.
This article belongs to the Proceedings The 8th International Electronic Conference on Medicinal Chemistry

Abstract

A series of novel indole derivatives containing ester groups, halogen, epoxy and short-chain aliphatic hydrocarbons were designed, synthesized and evaluated for their antibacterial activities. Most of the compounds showed relatively excellent inhibitory activities against different strains (including a multidrug-resistant clinical isolate). Compounds 3f, 3o and 3r showed the strongest inhibitory activity (mic of 2–32 μg/mL). Compounds 3f, 3h, 3i, 3o and 3r with antibacterial activity were not cytotoxic against RAW 264.7 mouse macrophages. The structure–activity relationship analysis and docking studies showed that the halogens as well as aliphatic hydrocarbons could enhance the antibacterial ability and reduce the toxicity of the indole compounds.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ECMC2022-13172/s1.

Author Contributions

Conceptualization, X.P.; methodology, X.P.; experiment, K.Y., software, K.Y.; validation, X.P.; formal analysis, K.Y.; investigation, K.Y.; resources, K.Y.; data curation, K.Y.; writing—original draft preparation, K.Y.; writing—review and editing, X.P.; supervision, X.P. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by National Natural Science Foundation of China (82160651); The Open Project of Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University (K202103); The Open Project of Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education (XPRU202004); Youth Innovative Talent Cultivation Projects of Shihezi University (CXPY202005) and The Open Sharing Fund for the Large-scale Instruments and Equipments of Shihezi University.

Institutional Review Board Statement

The animal study protocol was approved by the Ethics Committee of the First Affiliated Hospital, School of Medicine, Shihezi University (protocol code A2022-209-01).

Data Availability Statement

The data presented in this study are available in the article.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.